Similarly, Tanimoto et al. (2017) found that vorinostat combined with osimertinib reverses the resistance of EGFR-mutated NSCLC cell lines presenting the BIM deletion polymorphism. This evidence concerns the gene EGFR and non-small cell lung carcinoma.